Perspective Complete Prescribing Info OPDIVO® (nivolumab) is indicated for your treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or just after 3 or more strains of systemic therapy that includes autologous HSCT